We have shown that O-GlcNAc transferase (OGT) is overexpressed in prostate cancer, making this enzyme a potential drug target for the disease (Itkonen et al. 2013; Itkonen et al. 2021). The gene discussed is OGT; the disease is prostate carcinoma.